NEW YORK (GenomeWeb) – Response Genetics today said it has executed a commercial agreement with the Knight Diagnostic Laboratories at Oregon Health & Science University to launch a next-generation sequencing-based lung cancer panel.

The Knight Diagnostic-developed panel provides "full gene sequencing of the actionable genes for lung cancer rather than detection only of so-called hot spots," Response Genetics said. It added that it expects to market the panel immediately.

Financial and other terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.